Lung Cancer | Dr. Tony Talebi discusses the Treatment of Stage 4 Non Small Cell Lung Cancer

http://youtu.be/CDk_FZk3lDc Dr Tony Talebi discusses the treatment of advanced stage 4 non small cell lung cancer with Dr. Jorge Gomez. For further discussion visit http://www.HemOnc101.com Treatment of stage 4 metastatic non-small cell lung cancer Lung cancer is the most common cancer worldwide, with an estimated 1,600,000 new cases and 1,380,000 deaths in 2008. In the United States, there will be an estimated 221,000 new cases of lung cancer and 157,000 deaths in 2010. The term lung cancer, or bronchogenic carcinoma, refers to malignancies that originate in the airways or pulmonary parenchyma. Approximately 95 percent of all lung cancers are classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). This distinction is essential for staging, treatment, and prognosis. Other cell types comprise about 5 percent of malignancies arising in the lung. A number of environmental and life-style factors have been associated with the subsequent development of lung cancer, of which cigarette smoking is the most important. Other Environmental factors have been associated with an increased risk for developing lung cancer. These include exposure to second-hand smoke, asbestos, radon, ionizing radiation, and polycyclic aromatic hydrocarbons. The World Health Organization classification for primary lung cancer recognizes four major histologic cell types: 1-Adenocarcinoma (including bronchioloalveolar carcinoma) 2-Squamous cell carcinoma 3-Large cell carcinoma 4-Small cell carcinoma Here, Dr. Tony Talebi discusses the treatment of stage 4 metastatic non-small cell lung cancer with Dr. Jorge Gomez including the symptoms and signs of lung cancer, diagnosis with endobronchial ultrasound guided biopsy, staging with CT scan or PET scan, other imaging modalities, genetic implications and treatment of metastatic stage 4 non small cell lung cancer including options of surgery, radiation therapy and chemotherapy including new biologic treatments bevacizumab (Avastin), cetuximab (Erbitux), erlotinib (Tarceva), and EGFR overexpression in lung cancer. Dr. Jorge Gomez credentials: Certifications American Board of Internal Med-Medical Oncology Specialties Hematology/Oncology - Internal Medicine Internal Medicine Roles Assistant Professor of Clinical Medicine University of Miami Sylvester Comprehensive Cancer Center Clinical Interests Non-small cell lung cancer Small cell lung cancer Research Interests Non-small cell lung cancer Small cell lung cancer Lung cancer in young adults Education 2001 Fellowship New York University School of Medicine 1997 Residency Pennsylvania Hospital 1995 Internship Pennsylvania Hospital